Alimera Sciences to Report Fourth Quarter and Full Year 2017 Results on February 28, 2018

ATLANTA, Feb. 14, 2018 (GLOBE NEWSWIRE) -- Alimera Sciences ALIM, a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2017, after the close of the financial markets on Wednesday, February 28, 2018.

An accompanying conference call will be hosted by Dan Myers, Chief Executive Officer and Rick Eiswirth, President and Chief Financial Officer to discuss the results. The call will be held at 9:00 AM ET, on Thursday, March 1, 2018. Please refer to the information below for conference call dial-in information and webcast registration.

Conference Details

Conference date: Thursday, March 1, 2018 9:00AM ET

Conference dial-in: 877-269-7756

International dial-in: 201-689-7817

Conference Call Name: Alimera Sciences' Fourth Quarter 2017 Results Call

Webcast Registration: Click Here

Following the live call, a replay will be available on the Company's website, www.alimerasciences.com, under "Investor Relations."

About Alimera Sciences

Alimera Sciences, founded in June 2003, is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera's commitment to retina specialists and their patients is manifest in its product and development portfolio designed to treat early- and late-stage diseases. For more information, please visit www.alimerasciences.com.

For press inquiries:

Katie Brazel

for Alimera Sciences

404-317-8361

kbrazel@bellsouth.net

For investor inquiries:

CG Capital

for Alimera Sciences

877-889-1972

investorrelations@cg.capital